Sanofi
NASDAQ:SNYDrug Manufacturers - General
-$0.31 today
- Market cap
- $113.15B
- Beta
- 0.28
- P/E (TTM)
- 8.5
- EPS (TTM)
- $8.60
- Dividend yield
- 5.62%
Volume 2.32M
Average 2.78M
SNY Pre-Tax Margin
Income before tax as a percentage of revenue.
SanofiNASDAQ: SNY
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin narrows to 6.7%
Pre-tax margin was 6.7% in Q2 FY2026, down 6.9 pp from a year earlier. On a trailing-twelve-month basis it was 10.6%, down 7.2 pp year over year. Over 3 fiscal years it narrowed by 11.7 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 12.9%
- Year-over-year change
- -2.4pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.9% | -2.4pp |
| FY2024 | 2024-12-31 | 15.3% | +0.6pp |
| FY2023 | 2023-12-31 | 14.7% | -9.9pp |
| FY2022 | 2022-12-31 | 24.6% | +4.6pp |
| FY2021 | 2021-12-31 | 20.0% | — |
Pre-Tax Margin vs competitors
How SNY compares with its peers on the latest reported figures
- SNY's LTM Jun 2026 pre-tax margin of 10.6% is the 8th highest of the 11 companies compared; the peer median is 22.8%.
- Its year-over-year change of -7.2 pp is the 8th highest of 11, against a peer median of +0.8 pp.
- Over three fiscal years its change of -11.7 pp compares with a peer median of +4.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 45.2% | +0.0 pp | +3.2 pp | |
| LTM Jun 2026 | 42.2% | +10.5 pp | +15.6 pp | |
| LTM Jun 2026 | 27.9% | -0.4 pp | +13.5 pp | |
| LTM Jun 2026 | 27.0% | +5.7 pp | -3.5 pp | |
| LTM Jun 2026 | 24.2% | +10.4 pp | +2.6 pp | |
| LTM Sep 2026 | 21.3% | +1.6 pp | +15.5 pp | |
| LTM Jun 2026 | 17.8% | +3.2 pp | +3.5 pp | |
| LTM Jun 2026 | 10.6% | -7.2 pp | -11.7 pp | |
| LTM Jun 2026 | 9.0% | -21.1 pp | +4.7 pp | |
| LTM Jun 2026 | 6.6% | -9.9 pp | -22.3 pp | |
| LTM Jun 2026 | -6.4% | -31.4 pp | +12.0 pp | |
| Peer median (excluding SNY) | 22.8% | +0.8 pp | +4.1 pp | |
Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.18B | 40.56B | 41.62B | 44.29B | 46.72B |
| Cost of Revenue | 12.26B | 11.88B | 12.63B | 13.21B | 13.05B |
| Gross Profit | 26.92B | 28.68B | 28.99B | 31.08B | 33.67B |
| Gross Margin | 68.7% | 70.7% | 69.7% | 70.2% | 72.1% |
| Research & Development | 5.69B | 6.5B | 6.51B | 7.39B | 7.84B |
| Selling, General & Admin | 9.56B | 8.74B | 8.93B | 9.18B | 10.24B |
| Operating Expenses | 18.79B | 18.52B | 22.03B | 23.83B | 24.07B |
| Depreciation & Amortization | 3.35B | 3.11B | 4.43B | 3.59B | 5.68B |
| EBITDA | 11.54B | 13.51B | 11.39B | 11.03B | 12.48B |
| EBITDA Margin | 29.5% | 33.3% | 27.4% | 24.9% | 26.7% |
| Operating Income | 8.13B | 10.16B | 6.96B | 7.25B | 9.6B |
| Operating Margin | 20.7% | 25.1% | 16.7% | 16.4% | 20.5% |
| Interest Income | 3.13M | 168.96M | 530.5M | 457.53M | 331M |
| Interest Expense | 377.37M | 384.8M | 512.82M | 622.58M | 626M |
| Other Income / Expenses | (289M) | (170M) | (845M) | (494M) | (3.58B) |
| Income Before Tax | 7.84B | 9.99B | 6.12B | 6.76B | 6.02B |
| Pre-Tax Margin | 20.0% | 24.6% | 14.7% | 15.3% | 12.9% |
| Income Tax Expense | 1.56B | 1.91B | 1.02B | 1.2B | 1.04B |
| Net Income | 6.22B | 8.37B | 5.4B | 5.56B | 7.81B |
| Net Margin | 15.9% | 20.6% | 13.0% | 12.6% | 16.7% |
| EPS (Basic) | 2.49 | 3.19 | 2.15 | 2.19 | 3.20 |
| EPS (Diluted) | 2.49 | 3.18 | 2.15 | 2.19 | 3.20 |
| Weighted Avg Shares | 2.51B | 2.5B | 2.5B | 2.5B | 2.44B |
| Weighted Avg Shares (Diluted) | 2.51B | 2.5B | 2.51B | 2.5B | 2.44B |
Sanofi
NASDAQ:SNY
Intrinsic Alpha fair value
Locked
Current Price
$47.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.